Cancer NetworkOriginal article
<![CDATA[AI-Based Pan-TEAD Inhibitor Wins FDA Fast Track Designation in Mesothelioma]]>
Phase 1ISM6331Positive
AI Analysis
Summary
ISM6331, an AI-based pan-TEAD inhibitor, received FDA Fast Track designation for mesothelioma treatment. Phase 1 trial data will be presented at ESMO Congress 2026.
Clinical Trial Data
Phase
1
Outcome Details
Phase 1 trial data to be presented at ESMO Congress 2026
Importance:7/10
Sentiment:
0.70
FDA Fast TrackPan-TEAD inhibitorAI-basedmesotheliomaoncology
Read the original article
Published by Cancer Network on July 29, 2026 2:30 PM